MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 14 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Mansoor Raza Mirza, Sudarshan Sharma, Jørn Herrstedt, Mark S. Shahin, David Cibula, Emily Fleming +14 more
2023· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
28
citations
affno abstractunlabeled
Response evaluation: beyond RECIST
E. A. Eisenhauer
2007· review· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
27
citations
affno abstractunlabeled
ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma
Brian A. Van Tine, Marcus O. Butler, Dejka M. Araujo, Melissa L. Johnson, Jade Clarke, David A. Liebner +8 more
2019· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
25
citations
affno abstractunlabeled
Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
Laurence Albigès, Brian I. Rini, John B.A.G. Haanen, Robert J. Motzer, C. Kollmannsberger, Sylvie Négrier +12 more
2019· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
25
citations
aboutno affno abstractunlabeled
Emotional expression and coping style in female breast cancer
Giovanna Manna, Elena Foddai, M.G. Di Maggio, Francesco Pace, G. Colucci, Vittorio Gebbia +1 more
2007· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
24
citations
affno abstractunlabeled
Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
R. Kristeleit, Ronnie Shapira‐Frommer, Ana Oaknin, Judith Balmañà, Isabelle Laure Ray-Coquard, Susan M. Domchek +11 more
2016· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
24
citations

How this was built: Screen · Findings · About